NKTR Stock Overview
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Nektar Therapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.09 |
| 52 Week High | US$11.59 |
| 52 Week Low | US$1.99 |
| Beta | 0.92 |
| 1 Month Change | 29.29% |
| 3 Month Change | -18.04% |
| 1 Year Change | -70.46% |
| 3 Year Change | -86.33% |
| 5 Year Change | -95.86% |
| Change since IPO | -17.60% |
Recent News & Updates
Recent updates
Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely
Jan 24
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?
Aug 19Nektar: Time To Abandon Ship
Jul 17Nektar promotes internal executive to CFO role
Jul 01We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully
May 11After A High-Profile Failure In Melanoma, Nektar Therapeutics' Value Shifts To Its Early-Stage Pipeline
Apr 04Analysts Just Made A Major Revision To Their Nektar Therapeutics (NASDAQ:NKTR) Revenue Forecasts
Mar 09Nektar Therapeutics: Beaten Down By 2020
Jan 26We Think Nektar Therapeutics (NASDAQ:NKTR) Can Easily Afford To Drive Business Growth
Jan 13Nektar Therapeutics (NASDAQ:NKTR) Analysts Just Trimmed Their Revenue Forecasts By 11%
Dec 09Nektar Therapeutics (NASDAQ:NKTR) Is In A Strong Position To Grow Its Business
Oct 05Nektar Therapeutics' Short Covering Surges By 200% In 2 Weeks
Sep 29Nektar Sends Shot Across Bristol Myers Squibb's Bow With Big Pfizer Collaboration
Sep 23Mr. Manipulation Meets Ms. Opportunity At The Nektar Cocktail Party
Aug 27Nektar In Renal Cell Carcinoma: An Overview
Jul 10We Think Nektar Therapeutics (NASDAQ:NKTR) Can Easily Afford To Drive Business Growth
Jul 06Nektar Therapeutics shares rise on narrower Q1 loss
May 07We Think Nektar Therapeutics (NASDAQ:NKTR) Can Easily Afford To Drive Business Growth
Apr 05Nektar Therapeutics (NASDAQ:NKTR) Analysts Just Slashed This Year's Estimates
Feb 28Have Nektar Therapeutics (NASDAQ:NKTR) Insiders Been Selling Their Stock?
Feb 19Would Shareholders Who Purchased Nektar Therapeutics' (NASDAQ:NKTR) Stock Three Years Be Happy With The Share price Today?
Jan 25
Nektar to sell Adynovate, Movantik Royalties for $150M
Dec 22Nektar Therapeutics (NASDAQ:NKTR) Is In A Strong Position To Grow Its Business
Dec 21Nektar Therapeutics raised to ‘Hold’ from ‘Sell’ at CFRA on encouraging clinical data
Dec 16Dosing underway in Nektar Therapeutics' study of NKTR-255+cetuximab in head, neck and colorectal cancer
Dec 15Shareholder Returns
| NKTR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 18.4% | -0.5% | 1.7% |
| 1Y | -70.5% | 4.6% | -9.6% |
Return vs Industry: NKTR underperformed the US Pharmaceuticals industry which returned 4.3% over the past year.
Return vs Market: NKTR underperformed the US Market which returned -8.5% over the past year.
Price Volatility
| NKTR volatility | |
|---|---|
| NKTR Average Weekly Movement | 9.8% |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: NKTR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: NKTR's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 740 | Howard Robin | https://www.nektar.com |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company’s products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin’s lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates.
Nektar Therapeutics Fundamentals Summary
| NKTR fundamental statistics | |
|---|---|
| Market Cap | US$580.78m |
| Earnings (TTM) | -US$454.15m |
| Revenue (TTM) | US$95.04m |
6.1x
P/S Ratio-1.3x
P/E RatioIs NKTR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NKTR income statement (TTM) | |
|---|---|
| Revenue | US$95.04m |
| Cost of Revenue | US$21.57m |
| Gross Profit | US$73.48m |
| Other Expenses | US$527.63m |
| Earnings | -US$454.15m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.42 |
| Gross Margin | 77.31% |
| Net Profit Margin | -477.85% |
| Debt/Equity Ratio | 0% |
How did NKTR perform over the long term?
See historical performance and comparison